CD30 ligand could be a new therapeutic target for central nervous system autoimmunity

Publisher： John Wiley & Sons Inc

E-ISSN： 1759-1961|6|2|111-112

ISSN： 1759-1961

Source： CLINICAL AND EXPERIMENTAL NEUROIMMUNOLOGY, Vol.6, Iss.2, 2015-05, pp. : 111-112

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nanoformulation of Brain‐Derived Neurotrophic Factor with Target Receptor‐Triggered‐Release in the Central Nervous System

By  

ADVANCED FUNCTIONAL MATERIALS, Vol. 28, Iss. 6, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Central nervous system has a lymphatic system: What's next?

By  

CLINICAL AND EXPERIMENTAL NEUROIMMUNOLOGY, Vol. 6, Iss. 4, 2015-11 ,pp. : 347-348

John Wiley & Sons Inc

Access to resources Recommend Favorite

Accumulating knowledge of the barrier system in the central and peripheral nervous system: What's next?

By  

CLINICAL AND EXPERIMENTAL NEUROIMMUNOLOGY, Vol. 6, Iss. 2, 2015-05 ,pp. : 109-110

John Wiley & Sons Inc

Access to resources Recommend Favorite

An Injectable, Self‐Healing Hydrogel to Repair the Central Nervous System

By  

ADVANCED MATERIALS, Vol. 27, Iss. 23, 2015-06 ,pp. : 3518-3524

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mechanisms of immunological tolerance in central nervous system inflammatory demyelination

By  

CLINICAL AND EXPERIMENTAL NEUROIMMUNOLOGY, Vol. 6, Iss. 3, 2015-08 ,pp. : 264-274

John Wiley & Sons Inc

Access to resources Recommend Favorite